Clovis Oncology

Overview

Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right drMore >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$95.00
Change (%) Stock is Down 1.78 (1.84%)
Intraday High$96.70
Intraday Low$92.33
Volume2,535,843
Data as of 06/23/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle  
06/21/17Clovis Oncology Announces Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)--Jun. 21, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 511,363 shares. The offering, including the sale of the additional shares, is expected to close on June 26, 2017, subject to customary closing conditions. Clovis Oncology intends to use th... 
Printer Friendly VersionDownload PDF
06/20/17Clovis Oncology Announces Upsizing and Pricing of Public Offering of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)--Jun. 20, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 3,409,091 shares of its common stock at $88.00 per share, before underwriting discounts and commissions. The size of the offering was upsized from $250 million to $300 million. In addition, the underwriters have a 30-day option to purchase up to an additional 511,363 shares of common stock from Clovis Onco... 
Printer Friendly VersionDownload PDF
06/19/17Clovis Oncology Announces Proposed Offering of Common Stock
BOULDER, Colo.--(BUSINESS WIRE)--Jun. 19, 2017-- Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $250 million. All shares of the common stock to be sold in the offering will be offered by Clovis Oncology. Clovis Oncology intends to use the net proceeds of the offering for general corporate purposes, including... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
There are currently no events scheduled.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.